Technology areas: Computing & Software • Transportation, E-Commerce & Mechanical Systems
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Hem Pharma Inc. has 3 pending office actions in the Computing & Software technology area. These actions are handled by 3 distinct examiners. The portfolio is distributed across 3 distinct art units, meaning each action is being reviewed by a different examiner in a different group. This distribution across 3 distinct art units suggests that the company's innovations cover multiple specialized sub-fields within computing.
ANDERSON-FEARS, KEENAN NEIL is the busiest examiner, with 1 busiest examiner pending office action. This represents one of the 3 pending office actions. Since there are 3 pending actions, 3 distinct examiners, and 3 distinct art units, the company's current software prosecution is entirely decentralized. Practitioners should monitor the different art units to ensure that the prosecution of the 3 pending office actions remains consistent despite the lack of centralized oversight.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANDERSON-FEARS, KEENAN NEIL | 1 | 15.4% | +37.5% |
| RAPILLO, KRISTINE K | 1 | 28.8% | +26.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17793855 | METHOD AND SERVER FOR PROVIDING INTESTINAL MICROBIOME ANALYSIS RESULT | RAPILLO, KRISTINE K | 46d overdue |
| 18458297 | METHOD AND DIAGNOSTIC APPARATUS FOR DETERMINING HYPERGLYCEMIA USING MACHINE LEARNING MODEL | ANDERSON-FEARS, KEENAN NEIL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17793855 | METHOD AND SERVER FOR PROVIDING INTESTINAL MICROBIOME ANALYSIS RESULT | RAPILLO, KRISTINE K | 46d overdue |
| 18458297 | METHOD AND DIAGNOSTIC APPARATUS FOR DETERMINING HYPERGLYCEMIA USING MACHINE LEARNING MODEL | ANDERSON-FEARS, KEENAN NEIL | — |
| Art Unit | Apps |
|---|---|
| 2124 | 1 |
| 3682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18458297 | METHOD AND DIAGNOSTIC APPARATUS FOR DETERMINING HYPERGLYCEMIA USING MACHINE LEARNING MODEL | ANDERSON-FEARS, KEENAN NEIL | 2124 | §101§103§112 | Non-Final OA | — | Pending | Aug 30, 2023 |
| 17793855 | METHOD AND SERVER FOR PROVIDING INTESTINAL MICROBIOME ANALYSIS RESULT | RAPILLO, KRISTINE K | 3682 | §101§103 | Final Rejection | 46d overdue | Pending | Dec 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHem Pharma Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Keenan Neil Anderson-Fears has the most, with 1 of Hem Pharma Inc.'s pending office actions.
Mostly Computing & Software (USPTO Tech Center 2100), based on where its pending office actions are examined.
